For example, the high expression of the methyltransferase DNMT3B was related to poor prognosis in AML patients.31 Myelodysplastic syndrome (MDS) and AML-mesenchymal stem cells (MSCs) displayed global hypomethylation and underexpression of the methyltransferase DNMT1 and the methyl-binding protein UHRF1.32 Changes in the methylation patterns of methyl-binding proteins, MBD2 and MeCP2, were observed in B-chronic lymphocytic leukemia (CLL).33 The recurrent change in DNA methylation profile in AML and ALL could predict patients’ prognosis and treatment efficacy.34 This evidence concerns the gene DNMT3B and acute myeloid leukemia.